Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.41 |
| ▸ | ARG1 | P05089 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15249668 | 0.98 | GSR (0.43) | GSRARG2ARG1LMNAPOLB | |
| SCHEMBL25660575 | 0.95 | GSR (0.42) | GSRARG2ARG1LMNAPOLB | |
| SCHEMBL18155642 | 0.94 | GSR (0.42) | GSRARG2ARG1LMNAPOLB | |
| SCHEMBL16360434 | 0.91 | GSR (0.41) | GSRARG2ARG1LMNAPOLB | |
| SCHEMBL18881039 | 0.91 | GSR (0.41) | GSRARG2ARG1LMNAPOLB | |
| SCHEMBL12028168 | 0.89 | ANPEP (0.41) | GSRLMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL25662308 | 0.84 | GRIN2D (0.38) | GSRHPGDANPEPALDH1A1CYP1A2 | |
| SCHEMBL25660587 | 0.84 | GRIN2D (0.38) | GSRHPGDANPEPALDH1A1CYP1A2 | |
| SCHEMBL19528476 | 0.80 | GSR (0.40) | GSRARG2ARG1PKMNOS2 | |
| SCHEMBL14036328 | 0.79 | EPHX1 (0.38) | TP53HPGDALOX12ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3572091-B1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-9975936-B2 | Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids | AMBRX, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9962450-B2 | Method of treating heart failure with modified relaxin polypeptides | AMBRX, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | AMBRX, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170096463-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9567386-B2 | Therapeutic uses of modified relaxin polypeptides | AMBRX, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20120190827-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120041180-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110294161-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110207914-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | AMBRX, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110124880-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110118501-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7939496-B2 | Linked to polyoxyethylene glycol via oximination; improved half-life | AMBRX, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20110015345-A1 | Modified FGF-23 Polypeptides and Their Uses | AMBRX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | APOB, APOL1, HDLBP | GSR 4050/4885ARG2 2371/4885ARG1 1284/4885 |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | GSR 3523/4885ARG2 389/4885ARG1 2084/4885 |
| US-20170096463-A1 | Modified FGF-21 Polypeptides and Their Uses | FGF2, FGF1, FGF23 | GSR 4651/4885ARG2 2151/4885ARG1 1243/4885 |
| US-20110118501-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | GSR 2147/4885ARG2 35/4885ARG1 83/4885 |
| US-20120041180-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | GSR 3439/4885ARG2 1185/4885ARG1 573/4885 |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | FGF2, FGF1, FGF23 | GSR 4651/4885ARG2 2151/4885ARG1 1243/4885 |
| US-20110124880-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | GSR 2147/4885ARG2 35/4885ARG1 83/4885 |
| US-20110015345-A1 | Modified FGF-23 Polypeptides and Their Uses | FGF23, FGF2, FGF1 | GSR 4538/4885ARG2 2778/4885ARG1 1966/4885 |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | GSR 2028/4885ARG2 112/4885ARG1 126/4885 |
| US-20110207914-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | GSR 3439/4885ARG2 1185/4885ARG1 573/4885 |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | RXFP1, RXFP2, RXFP3 | GSR 2983/4885ARG2 42/4885ARG1 35/4885 |
| US-20120190827-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | GSR 3439/4885ARG2 1185/4885ARG1 573/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | GSR 3276/4885ARG2 57/4885ARG1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.